Ключевые слова
Как цитировать
Аннотация
Рассмотрены лекарственные препараты, применяемые для лечения меланомы, начиная с дакарбазина и кончая иммунотерапевтическими препаратами, принятыми для практического использования в последние годы. Для каждого препарата охарактеризованы его эффективность по разным параметрам, основные мишени и механизмы действия.
Библиографические ссылки
Дементьева Н.П., Корман Д.Б. Нитрозометилмочевина - 30 лет изучения и применения для лечения онкологических больных // Вопр.онкол. - 2001. - № 6. - С. 55-661.
Корман Д.Б., Микаэлян С.Г, Пинес Е.В., Снимщиков В.А. Влияние химиотерапии на выживаемость больных с диссеминированной меланомой кожи // Сов. медицина. - 1987. - № 10. - С.102-105.
Корман Д.Б. Мишени и механизмы действия противоопухолевых препаратов. - М.: Практическая медицина, 2014. - 333 с.
Эммануэль Н.М., Корман Д.Б., Островская Л.А. и др. Нитрозоалкилмочевины - новый класс противоопухолевых препаратов. - М.:Наука, 1978. - 295 с.
Agarwala S.S., Kirkwood J.M., Glore M. et al. Temozolo-mide for the treatment of brain metastases associated with metastatic melanoma: a phase II study // J. Clin. Oncol. - 2004. - Vol. 22. - P. 2101-2107.
Avrie M.F., Aamadal S., Grob J.J. et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study // J. Clin. Oncol. -2004. - Vol. 22. - P. 1118-1125.
Carbe C., Eigantler T.K., Keilholz U. et al. Systematic review of medical treatment in melanoma: current status and future prospects // Oncologist. - 2011. - Vol. 16. - P. 5-24.
Carvajal R.D., Sosman J.A., Queredo J.F. et al. Effect of selumetinibe versus chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial // JAMA. - 2014. - Vol. 311. - P. 2397-2405.
ComachoL.H., Antonia S., Sosman J.et al. Phase I/II trial of tremelimumab in patients with metastatic melanoma // J. Clin. Oncol. - 2009. - Vol. 27. - P. 1075-1081.
Duan L., Mukherjel E.M., Narayen D. Tailoring the treatment of melanoma: implications for personalized medicine // Yal. J. Biol. Med. - 2015. - Vol. 88. - P. 389-395.
Dummer R., Goldinger S.M., Tutschi C. et al. Vemurafenib in patients with BRAF (V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study // Eur. J. Cancer. - 2014. - Vol. 50. - P. 611-621.
Eggermont A.M., Kirkwood J.M. Re-eveluating the role of dacarbazine in metastatic melanoma: whay have we learned in 30 years // Eur. J. Cancer. - 2004. - Vol. 40.- P. 1825-1836.
Eggermont A.M, Chiarion-Sileni V., Garob J.J. et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomized double-blinde, phase III trial // Lancet Oncol.- 2015. - Vol. 16. - P. 522-530.
Eigentler T.K., Gutzmer R., Hauschild Y et al. Adjuvant treatment with pegylated interferon-alfa-2a versus low-dose interferon-alfa-2a in patients with high-risk melanoma: a randomized phase III De C06 trial // Ann. Oncol. - 2016. - Vol. 27. - P. 1625-1632.
Falchook G., Lewis K.D., Infante J.R. et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase I dose-escalation trail // Lancet Oncol. - 2012. - Vol. 13. - P. 782-789.
Flaherty K.T., Infante J.R., Daud et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations // N. Engl. J. Med. - 2012. - Vol. 367. - P. 16941703.
Flaherty L., Hami O., Linette G. et al. A single-arm, open-label, expanded eccess study of vemurafenib in patients with metastatic melanoma in the United States // Cancer. - 2014. - Vol. 20. - P. 18-24.
Greg S.L. Talmogene laherparepvec: first global approval // Drugs. - 2016. - Vol. 76. - P. 147-154.
Hauschild A., Grob J.J., Dewidov L.V. et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicenter, open-label, phase III, randomized controlled trial // Lancet. - 2102. - Vol. 380. - P. 358-365.
Hersh E.M., O'Day S.J., Powdeily J. et al. A phase II multicenter study of ipilimumab with and without dacarbazine in chemotherapy-naive patients with advanced melanoma // Invest.New Drugs. - 2011. - Vol. 29. - P. 489-498.
Ives N.J., Stow R.L., Lovigan P., Wheatly K. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 12 trials involving 2621 patients // J. Clin. Oncol. - 2007. - Vol. 25. - P. 5426-5436.
Jiang G., Li.R.H., Sun C. et al. Efficacy ana safety between temozolamide alone and telozolamide-based double therapy for malignant melanoma: a meta-analysis // Tumour Biol. - 2014. - Vol. 35. - P. 315-322.
Johnson D.B., Puzanov I., Velley M.C. Talmogne laherparepvec (T-VEC) for the treatment of advanced melanoma // Immenother. - 2015. - Vol. 7. - P. 611-619.
Kaufman H.L., Amatruda T., Reid T. et al. Systemic versus local response in melanoma patients terated with talmogene laherpareprec from a multi-instititional phase II study // J. Immunother Cancer. - 2016. - Vol. 4. - P. 12. - 10 1186/s4042-016-0116-2 DOI: 10.1186/s4042-016-0116-2
Khan N., Gucalp R., Shapira I. Evolving concepts: immunity in oncology from targets to treatment // J. Clin. Oncol. - 2015. - Article d.847363. - apr28. - DOI: 10.1155/2015/847383
Kirkwood J.M., Bastholt L., Robert C. et al. Phase II open-label, randomized trial of the MEK1/2 inhibitor selumetinib in patients with advanced melanoma // Clin. Cancer Res. - 2012. - Vol. 18. - P. 555-567.
Larkin J., DelVeccio M., Ascierto P.A. et al. Vemurafenib in patients with BRAF (V600) mutated metastatic melanoma: open-label, multicenter, safety study // Lancet Oncol. -2014. - Vol. 15. - P. 436-444.
Larkin J., Ascierto P.A., Dreno B. et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma // N. Engl. J. Med. - 2014. - Vol. 371. - P. 1867-1876.
Luke J.J., Hodi F.S. Ipilimumab, vemurafenib, dabrafenib and trametinib: synergistic competations in the clinical management of BRAF mutant malignant melanoma // Oncologist. - 2013. - Vol. 18. - P. 717-725.
Liong G.V., Stroykovskiy D., Goga S. et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma // N. Engl. J. Med. - 2014. - Vol. 371. - P. 1877-1888.
Maio M., Grob J.J., Aamdal S. et al. Five-year survival rates for treatment-nave patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial // J.Clin.Oncol. - 2015. - Vol. 33. - P. 1191-1196.
Malas S., Harrasser M., Lacy K.E., Karagionnis S.H. Antibody therapyies for melanoma: new and emerging opportunities to activate immunity (review) // Oncol. Rep. - 2014. - Vol. 32. - P. 875-886.
Mangana J., Cheng P.F., Schidler K.et al. Analysis of BRAF and NRAS mutation status in advanced melanoma patients treated with anti-CTLA-4 antibodies: association with overall survival // PLoS One. - 2015. - Vol. 10 (10). - el 0139438.
McArthur G.A., Chapman P.B., Robert C. et al. Safety and efficacy of vemurafenib in BRAF V600E and BRAF V600K mutation-positive melanoma (BRIM-3); extended follow-up of phase3, randomized open-label study // Lancet Oncol. - 2014. - Vol. 15. - P. 323-332.
Menzies A.M., Long G., Murali R. Dabrafenib and its potential for the treatment of metastatic melanoma // Drug Des. Devel. Ther. - 2012. - Vol. 6. - P. 391-405.
Menzies A.M., Long G.V. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma // Clin.Cancer Res. - 2014. - Vol. 20. - P. 2035-2043.
Metcalfe W., Anderson J., Trinth V., Hwu W.J. Antiprogrammed cell death-1 (PD1) monoclomal antibodies in treating advanced melanoma // Discov. Med. - 2015. - Vol. 106. - P. 393-401.
Michelin O., Holler C. Gaining momentum: new options and opportunities for the treatment of advanced melanoma // Cancer Treat. Rev. - 2015. - Vol. 41. - P. 660-670.
Middleton M.R., Giol J.J., Aaronson N. et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic melanoma // J. Clin. Oncol. - 2008. - Vol. 18. - P. 158-166.
Mocellin S., Pasquali S., Rossi C.R., Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematric review and meta-analysis // J. Natl. Cancer Inst. - 2010. - Vol. 102. - P. 493-501.
Ott P.A., Hodi F.S., Robert C. CTLA-4 and PD1/PDL1 blackage: new immuno-therapeutic modalities with durable clinical benefit in melanoma patients // Clin. Cancer Res. - 2013. - Vol. 19. - 5300.
Patel S.P., Woodman S.E. Profile of ipilimumab and its role in the treatment of metastatic melanoma // Drug Des. Devel. Ther. - 2011. - Vol. 5. - P. 489-495.
Petrolla T, Quirt I., Verma S. et al. Single-agent interleukin-2 in the treatment of metastatic melanjoma // Curr. Oncol. - 2007. - Vol. 14. - P. 21-26.
Prietro P.A., Yang J.C., Sherry R.M. et al. CTLA-4 blockage with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma // Clin. Cancer Res. - 2012. - Vol. 18. - P. 2039-2047.
Ribas A., Kefford R., Marshall H.A. et al. Phase III randomized clinical trial comparing tremelimumab with standart of care chemotherapy in patients with advanced melanoma // J. Clin. Oncol. - 2013. - Vol. 31. - P. 616622.
Ribas A., Puzanov I., Dummer R. et al. Pembrolizumab versus investigator choice chemotherapy for ipilimumab-refractory melanoma ( KEYNOTR-002): a randomized, controlled, phase 2 trial // Lancet Oncol. - 2015. - Vol. 18. - P. 908-918.
Ribas A., Hamid O., Daud A. et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma // JAMA. - 2016. - Vol. 135. - P. 1600-1609.
Robert C., Dummer R., Gutzmer R. et al. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomized study // Lancet Oncol. - 2013. - Vol. 14. - P. 733-740.
Robert C., Schadendorf D., Messina M. et al. Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control // Clin. Cancer Res. - 2013. - Vol. 19. - P. 2232-2230.
Robert C., Ribas A., Wolckok J.D. et al. Anti-programmed -death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomized dose-comparison cohort of a phase I trial // Lancet. - 2014. - Vol. 384. - P. 1109-1117.
Robert C., Karaszewska B., Schacter J. et al. Improved overall survival in melanoma with combined dabrafenib and trametinib // N. Engl. J. Med. - 2015. - Vol. 372. - P. 30-39.
Robert C., Schacter J., Long G.V. et al. Pemobrolizumab versus ipilimumab in advanced melanoma // N. Engl. J. Med. - 2015. - Vol. 372. - P. 2521-253.
Schadendorf D., Hodi F.S., Robert C. et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unrectable or metastatic melanoma // J. Clin. Oncol. - 2015. - Vol. 33. - P. 1889-1894.
Scott L.L. Nivolumab: a review in advanced melanoma // Drugs - 2015. - Vol. 12. - P. 1413-1424.
Serrone L., Zeuli H., Sega F.M., Cognett F. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview // J. Exp. Clin. Cancer - 2000. - Vol. 19. - P. 21-34.
Sullivan R.J., Flaherty K. Resistance to BRAF-targed therapy in melanoma // Eur. J. Cancer. - 2013. - Vol. 99. - P. 1294-1304.
Topalian S.L., Sznol M., McDermott D.F. et al. Survaival, durable tumor remission and long-term safety in patients with advanced melanoma receiving nivolumab // J.Clin. Oncol. - 2014. - Vol. 32. - P. 1020-1030.
Tran K.H., Cheng M.Y, Mitra A. et al. MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy // Drug Devel. Ther. - 2016. - Vol. 10. -P. 43-52.
Vallet H., Caillet A., Weiss N. et al. Pembrolizumab-induced necrotic myositis in a patient with metastatic melanoma // Ann. Oncol. - 2016. - mdw126. DOI: 10.1093/annonc/
Vockens C.J., Goldinger S.M., Loquai C. et al. The price of tumor control: an analysis of a rare side effects of an-ti-CTLA-4 therapy in a metastatic melanoma from the ipilimumab network // PLoS One. - 2013. - Vol. 8. - e53745.
Wolchok J. How recent advances in immunotherapy are changing the standart of care for patients with metastatic melanoma // Ann. Oncol. - 2012. - Vol. 33. - Suppl.8. - P. 15-21.
Wolchok J.D., Hodi F.S., Weber J.S. et al. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma // Ann. N.Y Acad. Sci. - 2013. - Vol. 129. - P. 1-13.
Wolchok J.D., Weber J.S., Maio M. et al. Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials // Ann. Oncol. - 2013. - Vol. 24. - P. 2174-2180.
Yang H.S., Chapman P.B. The history and future of chemotherapy for melanoma // Hematol. Oncol. Clin. North Am. - 2009. - Vol. 23. - P. 583-590.
Это произведение доступно по лицензии Creative Commons «Attribution-NonCommercial-NoDerivatives» («Атрибуция — Некоммерческое использование — Без производных произведений») 4.0 Всемирная.
© АННМО «Вопросы онкологии», Copyright (c) 2017